Abstract:Background Patient-derived tumor xenograft models have been established and increasingly used for preclinical studies of targeted therapies in recent years. However, patient-derived non-small cell lung cancer (NSCLC) xenograft mouse models are relatively few in number and are limited in their degree of genetic characterization and validation. In this study, we aimed to establish a variety of patient-derived NSCLC models and characterize these for common genetic aberrations to provide more informative models for preclinical drug efficacy testing. Methods NSCLC tissues from thirty-one patients were collected and implanted into immunodeficient mice. Established xenograft models were characterized for common genetic aberrations, including detection of gene mutations within EGFR and KRAS, and genetic amplification of FGFR1 and cMET . Finally, gefitinib anti-tumor efficacy was tested in these patient-derived NSCLC xenograft models. Results Ten passable patient-derived NSCLC xenograft models were established by implantation of NSCLC specimens of thirty-one patients into immunodeficient mice. Genetic aberrations were detected in six of the models, including one model with an EGFR activating mutation (Exon19 Del), one model with KRAS mutation, one model with both KRAS mutation and cMET gene amplification, and three models with FGFR1 amplification. Anti-tumor efficacy studies using gefitinib demonstrated that the EGFR activating mutation model had superior sensitivity and that the KRAS mutation models were resistant to gefitinib. The range of gefitinib responses in the patient-derived NSCLC xenograft models were consistent with the results reported from clinical trials. Furthermore, we observed that patient-derived NSCLC models with FGFR1 gene amplification were insensitive to gefitinib treatment. Conclusions Ten patient-derived NSCLC xenograft models were established containing a variety of genetic aberrations including EGFR activating mutation, KRAS mutation, and FGFR 1 and cMET amplification. Gefitinib anti-tumor efficacy in these patient-derived NSCLC xenografts containing EGFR and KRAS mutation was consistent with the reported results from previous clinical trials. Thus, data from our panel of patient-derived NSCLC xenograft models confirms the utility of these models in furthering our understanding of this disease and aiding the development of personalized therapies for NSCLC patients.

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases

Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection.

Differential Response to EGFR- and VEGF-targeted Therapies in Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma and Related Metastases

Establishment of Patient-Derived Gastric Cancer Xenografts: a Useful Tool for Preclinical Evaluation of Targeted Therapies Involving Alterations in HER-2, MET and FGFR2 Signaling Pathways

Antitumor Effect of FP3 in Combination with Cetuximab on Patient-Derived Tumor Tissue Xenograft Models of Primary Colon Carcinoma and Related Lymphatic and Hepatic Metastases

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Establishing A Patient-Derived Colorectal Cancer Xenograft Model For Translational Research

Antitumor Effect of FP3 on a Patient-Derived Tumor Tissue Xenograft Model of Rectal Carcinoma.

Personalized Primary Tumor Xenograft Model Established for the Pre-Clinical Trial to Guide Postoperative Chemotherapy

Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenograft Models with Genetic Aberrations Within EGFR, KRAS and FGFR1: Useful Tools for Preclinical Studies of Targeted Therapies

Preparation and Application of Patient-Derived Xenograft Mice Model of Colorectal Cancer

In Vitro Vascularized Immunocompetent Patient-Derived Model to Test Cancer Therapies.

Characterization and Validation of Potential Therapeutic Targets Based on the Molecular Signature of Patient-Derived Xenografts in Gastric Cancer

A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases

Patient-derived bladder cancer xenograft models reveal VEGF and CDK4 enhancing tumor metastasis behavior

A Preliminary Study on the Establishment of the PDTX Model

A preliminary discussion on establishment of patient-derived tumor xenograft (PDTX) model and testing of pharmacodynamics

Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study

Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis